A response to “Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study”-Reference-Cited by-同舟云学术

A response to “Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study”

Published:2023-06-15 Issue:5 Volume:45 Page:1307-1308
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Shang Xiang^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy

Link

https://link.springer.com/content/pdf/10.1007/s11096-023-01613-w.pdf

Reference6 articles.

1. Scherf-Clavel M, Frantz A, Eckert A, et al. Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study. Int J Clin Pharm. 2023. https://doi.org/10.1007/s11096-023-01588-8.

2. Bakken GV, Molden E, Knutsen K, et al. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012;40(9):1778–84. https://doi.org/10.1124/dmd.112.045237.

3. Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62. https://doi.org/10.1055/s-0043-116492.

4. Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: A systematic review and meta-analysis. JAMA Psychiatry. 2021;78(3):270–80. https://doi.org/10.1001/JAMA.2020.3643.

5. Stäuble CK, Lampert ML, Mikoteit T, et al. Severe adverse drug reactions to quetiapine in two patients carrying CYP2D6*4 variants: a case report. Int J Mol Sci. 2021;22(12):6480. https://doi.org/10.3390/ijms22126480.